会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明授权
    • Azabenzofuran substituted thioureas; inhibitors of viral replication
    • 氮杂苯并呋喃取代的硫脲; 病毒复制抑制剂
    • US07439374B2
    • 2008-10-21
    • US11029910
    • 2005-01-05
    • Andrew ThurkaufDawei ChenAvinash PhadkeShouming LiMilind Deshpande
    • Andrew ThurkaufDawei ChenAvinash PhadkeShouming LiMilind Deshpande
    • C07D401/02A61K31/44
    • A61K31/00A61K31/4355C07D491/04
    • The present invention provides compounds of Formula 1, wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W, X, and Y are defined herein. Certain compounds of Formula 1 described herein possess potent antiviral activity. The invention also provides compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.
    • 本发明提供式1的化合物,其中变量Ar,A 1,A 2,A 3,A 4, R 5,R 6,R 7,V,W,X和Y在本文中定义。 某些本文所述的式1的化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式1化合物。 本发明还提供含有一种或多种式1化合物或这些化合物的盐,溶剂化物或酰化前药以及一种或多种药学上可接受的载体,赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效减少疾病体征或症状的式1化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染,特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法,还包括治疗其它动物(包括患有传染病的家畜和驯养的伴侣动物)的方法。 治疗方法包括施用作为单一活性剂的式1化合物或与一种或多种其它治疗剂组合施用式1的化合物。
    • 15. 发明授权
    • Thiazole compounds and methods of use
    • 噻唑化合物和使用方法
    • US08088806B2
    • 2012-01-03
    • US11431155
    • 2006-05-09
    • Suoming ZhangAvinash PhadkeCuixian LiuXiangzhu WangJesse QuinnDawei ChenVenkat GadhachandaShouming LiMilind Deshpande
    • Suoming ZhangAvinash PhadkeCuixian LiuXiangzhu WangJesse QuinnDawei ChenVenkat GadhachandaShouming LiMilind Deshpande
    • A61K31/426A61K31/44
    • C07D487/04C07D277/38C07D277/42C07D417/04C07D417/06C07D417/12C07D417/14C07D513/04
    • The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
    • 本发明提供式I的化合物,盐和水合物,其中变量Ar1,R2,R3,R4,r,q和t在本文中定义。 某些本文所述的式I化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。 本文所述的某些化合物抑制HCV复制复合物的组装。 本发明还提供含有一种或多种式I化合物或这些化合物的盐,溶剂化物或酰化前药以及一种或多种药学上可接受的载体,赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效降低疾病体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染,特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法,还包括治疗其它动物(包括患有传染病的家畜和驯养的伴侣动物)的方法。 治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。
    • 18. 发明申请
    • Azabenzofuran substituted thioureas; inhibitors of viral replication
    • 氮杂苯并呋喃取代的硫脲; 病毒复制抑制剂
    • US20050228013A1
    • 2005-10-13
    • US11029910
    • 2005-01-05
    • Andrew ThurkaufDawei ChenAvinash PhadkeShouming LiMilind Deshpande
    • Andrew ThurkaufDawei ChenAvinash PhadkeShouming LiMilind Deshpande
    • A61K31/00A61K31/4355A61K31/4741A61K38/21C07D471/04C07D491/02C07D491/04
    • A61K31/00A61K31/4355C07D491/04
    • The present invention provides compounds of Formula 1, wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W. X, and Y are defined herein. Certain compounds of Formula 1 described herein possess potent antiviral activity. The invention also provides compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.
    • 本发明提供式1的化合物,其中变量Ar,A 1,A 2,A 3,A 4, R 5,R 6,R 7,V,W,X和Y如本文所定义。 某些本文所述的式1的化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式1化合物。 本发明还提供含有一种或多种式1化合物或这些化合物的盐,溶剂化物或酰化前药以及一种或多种药学上可接受的载体,赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效减少疾病体征或症状的式1化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染,特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法,还包括治疗其它动物(包括患有传染病的家畜和驯养的伴侣动物)的方法。 治疗方法包括施用作为单一活性剂的式1化合物或与一种或多种其它治疗剂组合施用式1的化合物。